nach oben

International Journal of Clinical Oncology

Erschienen in:

18.04.2020 | Review Article

Management of gastrointestinal perforation related to radiation

verfasst von: Yawen Zheng, Wei Gao, Denial E. Spratt, Yuping Sun, Ligang Xing

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Perforation of gastrointestinal (GI) tract is a rare, but serious complication of abdominopelvic irradiation, and it can even occur several years after radiotherapy. As one of the symptoms of radiation enteropathy, it shares common features with other chronic complications and has its own characteristic at the same time. It has been reported that some systematic therapies, such as sorafenib and bevacizumab, could add the risk of radiation-induced GI perforation. The potential mechanisms of aggravated GI injury may be exacerbation of epithelial cell damage, microvascular damage or subsequent inflammatory response. The complicated situation makes it almost impossible to set uniform dose constraints for GI perforation prevention. The majority of cancer patients with GI perforation require emergency surgery, and there is no high quality evidence for supporting the use of any prevention measures. In this review, we summarize the clinical manifestation, risk factors, mechanism, and therapy of radiation-induced GI perforation. A comprehensive treatment plan is crucial to improve the quality of life for cancer survivors.

Qi WX, Sun YJ, Tang LN et al (2014) Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 89:394–403PubMedCrossRef

Bottoni C, Scambia G, Fagotti A et al (2018) The safety of bevazicumab for the treatment of ovarian cancer. Expert Opin Drug Saf 17:1107–1113PubMedCrossRef

Andreyev J (2005) Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 54:1051–1054PubMedPubMedCentralCrossRef

Yamashita H, Nakagawa K, Tago M et al (2006) Small bowel perforation without tumor recurrence after radiotherapy for cervical carcinoma: report of seven cases. J Obstet Gynaecol Res 32:235–242PubMedCrossRef

Ramirez PT, Levenback C, Burke TW et al (2001) Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol 82:150–155PubMedCrossRef

Harb AH, Abou FC, Sharara AI (2014) Radiation enteritis. Curr Gastroenterol Rep 16:383PubMedCrossRef

Teo MT, Sebag-Montefiore D, Donnellan CF (2015) Prevention and management of radiation-induced late gastrointestinal toxicity. Clin Oncol (R Coll Radiol) 27:656–667CrossRef

Andreyev HJ, Vlavianos P, Blake P et al (2005) Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist? Int J Radiat Oncol Biol Phys 62:1464–1471PubMedCrossRef

Andreyev J (2007) Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 8:1007–1017PubMedCrossRef

10.

Pathak R, Shah SK, Hauer-Jensen M (2019) Therapeutic potential of natural plant products and their metabolites in preventing radiation enteropathy resulting from abdominal or pelvic irradiation. Int J Radiat Biol 95:493–505PubMedPubMedCentralCrossRef

11.

Isohashi F, Yoshioka Y, Mabuchi S et al (2013) Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. Int J Radiat Oncol Biol Phys 85:728–734PubMedCrossRef

12.

Shadad AK, Sullivan FJ, Martin JD et al (2013) Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol 19:185–198PubMedPubMedCentralCrossRef

13.

Kelly P, Das P, Pinnix CC et al (2013) Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 85:e143–e149PubMedCrossRef

14.

George G, Lewis S, Chopra S et al (2020) A retrospective study of the dosimetric parameters and duodenal toxicity in patients with upper gastrointestinal and gynaecological cancers treated with radiation therapy. Clin Oncol (R Coll Radiol) 32:e53–e59CrossRef

15.

Verma J, Sulman EP, Jhingran A et al (2014) Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88:357–362PubMedCrossRef

16.

Vargas C, Martinez A, Kestin LL et al (2005) Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62:1297–1308PubMedCrossRef

17.

Jadon R, Higgins E, Hanna L et al (2019) A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiat Oncol 14:57PubMedPubMedCentralCrossRef

18.

Yeoh EK, Krol R, Dhillon VS et al (2016) Predictors of radiation-induced gastrointestinal morbidity: a prospective, longitudinal study following radiotherapy for carcinoma of the prostate. Acta Oncol 55:604–610PubMedCrossRef

19.

Carrington R, Staffurth J, Warren S et al (2015) The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiat Oncol 10:236PubMedPubMedCentralCrossRef

20.

Yoon H, Oh D, Park HC et al (2013) Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma. Strahlenther Onkol 189:541–546PubMedCrossRef

21.

Chopra S, Dora T, Chinnachamy AN et al (2014) Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys 88:630–635PubMedCrossRef

22.

Pollom EL, Deng L, Pai RK et al (2015) Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 92:568–576PubMedPubMedCentralCrossRef

23.

Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869PubMedCrossRef

24.

Inoue T, Kinoshita H, Komai Y et al (2012) Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol 10:167PubMedPubMedCentralCrossRef

25.

Barney BM, Markovic SN, Laack NN et al (2013) Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 87:73–80CrossRefPubMed

26.

Brade AM, Ng S, Brierley J et al (2016) Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 94:580–587PubMedCrossRef

27.

Muraoka T, Tsukuda K, Toyooka S et al (2011) Ileal perforation induced by acute radiation injury under gefitinib treatment. Int J Clin Oncol 16:774–777PubMedCrossRef

28.

Mach CM, Urh A, Anderson ML (2014) Bowel perforation associated with temsirolimus use in a recently irradiated patient. Am J Health Syst Pharm 71:919–923PubMedCrossRef

29.

Anker CJ, Grossmann KF, Atkins MB et al (2016) Avoiding severe toxicity from combined braf inhibitor and radiation treatment: consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 95:632–646PubMedPubMedCentralCrossRef

30.

Tang T, Abu-Sbeih H, Luo W et al (2019) Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 54:538–545PubMedCrossRef

31.

Tree AC, Jones K, Hafeez S et al (2018) Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer. Int J Radiat Oncol Biol Phys 101:1168–1171PubMedCrossRef

32.

Luke JJ, Lemons JM, Karrison TG et al (2018) Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol 36:1611–1618PubMedPubMedCentralCrossRef

33.

Stansborough RL, Bateman EH, Al-Dasooqi N et al (2018) Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFbeta), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. Int J Radiat Biol 94:645–655PubMedCrossRef

34.

Francois A, Milliat F, Guipaud O et al (2013) Inflammation and immunity in radiation damage to the gut mucosa. Biomed Res Int 2013:123241PubMedPubMedCentral

35.

Hasleton PS, Carr N, Schofield PF (1985) Vascular changes in radiation bowel disease. Histopathology 9:517–534PubMedCrossRef

36.

Bentzen SM (2006) Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6:702–713PubMedCrossRef

37.

Hong S, Gu Y, Gao Z et al (2014) EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells. Life Sci 119:28–33PubMedCrossRef

38.

Karamchandani DM, Chetty R (2018) Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol 71:665–671PubMedCrossRef

39.

Takatori K, Terashima K, Yoshida R et al (2014) Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol 49:1074–1080PubMedCrossRef

40.

Lawrie TA, Green JT, Beresford M et al (2018) Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev 1:D12529

41.

Klopp AH, Yeung AR, Deshmukh S et al (2018) Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol 36:2538–2544PubMedPubMedCentralCrossRef

42.

Samuelian JM, Callister MD, Ashman JB et al (2012) Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 82:1981–1987PubMedCrossRef

43.

Rao AD, Feng Z, Shin EJ et al (2017) A novel absorbable radiopaque hydrogel spacer to separate the head of the pancreas and duodenum in radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 99:1111–1120PubMedPubMedCentralCrossRef

44.

Reyngold M, Parikh P, Crane CH (2019) Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol 14:95PubMedPubMedCentralCrossRef

45.

Henson CC, Burden S, Davidson SE et al (2013) Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009896.pub2 CrossRefPubMedPubMedCentral

46.

Wedlake LJ (2018) Nutritional strategies to prevent gastrointestinal toxicity during pelvic radiotherapy. Proc Nutr Soc 77:357–368PubMedCrossRef

47.

Langsenlehner T, Renner W, Gerger A et al (2011) Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlenther Onkol 187:784–791PubMedCrossRef

48.

Thurner EM, Krenn-Pilko S, Langsenlehner U et al (2014) Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy. Strahlenther Onkol 190:304–309PubMedCrossRef

49.

Kroeze SG, Fritz C, Hoyer M et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37PubMedCrossRef

Titel: Management of gastrointestinal perforation related to radiation
verfasst von: Yawen Zheng
Wei Gao
Denial E. Spratt
Yuping Sun
Ligang Xing
Publikationsdatum: 18.04.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01662-5

Springer Medizin

Management of gastrointestinal perforation related to radiation

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

Fertility preservation and fulfillment of parenthood after treatment of hematological malignancies: results from the ‘Aftercare in Blood Cancer Survivors’ (ABC) study

Variations in clinical features and oncologic behaviors of T1 colorectal cancer according to tumor location

Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems

A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

Impact of a reduction in follow-up frequency on life expectancy in uterine cervical cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie